Key Takeaways:
- Stryker missed Q1 2026 adjusted EPS estimates, posting $2.60 versus the consensus of $2.98, partly due to a major cyberattack
- Net sales of around $6 billion in Q1 2026 grew 2.6% year over year, and the company maintained full-year guidance
- SYK stock trades near $306, down around 20% in the past year, from a 52-week high of $405
- SYK stock could rise from $306 to around $393 per share by December 2028
- That implies a total return of around 29%, or around 10% annualized over the next 2.6 years
What Happened?
Stryker Corporation (SYK) had a challenging first quarter in 2026, and a significant part of the difficulty was not related to its core business fundamentals. A cyberattack struck the company in March 2026, disrupting manufacturing operations and delaying surgeries for some patients. Stryker confirmed that the incident had a material impact on Q1 results.
The company brought in cybersecurity firm Unit 42 to investigate, and by late March, manufacturing was mostly restored with no active unauthorized access detected in its systems. But the damage to Q1 numbers was already done. Adjusted EPS came in at $2.60, missing the analyst estimate of $2.98. Net sales of around $6 billion grew only 2.6% year over year, below what investors had expected from this normally consistent grower.
Despite the miss, Stryker maintained its full-year guidance, and that signals real management confidence in a recovery. Net earnings actually rose 13.9% to $745 million, and the board declared a quarterly dividend of $0.88 per share.
Stryker also completed the acquisition of Amplitude Vascular Systems, adding an IVL (intravascular lithotripsy, a technique using sound waves to break up calcified blockages in arteries) platform to its vascular portfolio.
Spencer Stiles was also named President and Chief Operating Officer in December 2025, adding experienced leadership to drive operational execution. A new training partnership with Max Smart Hospital in India is also expanding Stryker’s robotic surgery presence in a fast-growing market. And the FDA updated use instructions for Stryker’s patient-fitted temporomandibular joint implants.
Here’s why Stryker stock could deliver attractive returns over the next several years as the cyberattack headwind fades and growth reaccelerates.
What the Model Says for SYK Stock
We analyzed the upside potential for Stryker stock based on its market leadership in orthopedic implants and surgical robotics, expected margin expansion from scale, and a durable long-term demand tailwind from aging global populations.
Based on estimates of 8.3% annual revenue growth, 27.2% operating margins, and a normalized P/E multiple of 19.5x, the model projects Stryker stock could rise from $306 to around $393 per share by December 2028.
That would be a 28.6% total return, or a 10% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for SYK stock:
1. Revenue Growth: 8.3%
Stryker has a strong track record of consistent, above-average revenue growth over long periods. The 5-year revenue compound annual growth rate stands at around 11.8%, and the 10-year rate is around 9.7%. Q1 2026 revenue of around $6 billion grew 2.6% year over year, but that pace was temporarily suppressed by the cyberattack disruption rather than any structural demand weakness.
Based on analysts’ consensus estimates, we used an 8.3% annual revenue growth rate. The forward 2-year consensus revenue compound annual growth rate is around 8.5%, which aligns very closely with our assumption. This reflects continued demand for orthopedic implants, surgical robotics, and Stryker’s growing neurotechnology portfolio. The Amplitude Vascular Systems acquisition also adds a new and distinct revenue stream.
Growth in emerging markets, particularly the expanding robotic surgery training partnership in India, could provide incremental upside to this estimate over the coming years as those markets develop.
2. Operating Margins: 27.2%
Stryker operates with strong margins for a medical device company. The LTM gross margin is around 64.7%, and the LTM EBIT margin stands at around 22.5%. These metrics reflect the company’s pricing power and operating leverage across its diversified and highly differentiated product portfolio.
Based on analysts’ consensus estimates, we used a 27.2% operating margin target. This represents meaningful improvement over current trailing margins and assumes Stryker continues to benefit from scale economies as robotic surgery and software-assisted procedures grow as a share of total revenue.
The cyberattack added one-time costs in Q1 2026 but should not affect the longer-term margin trajectory. And the company’s forward 2-year EBITDA compound annual growth rate of around 9.9% suggests analysts expect a healthy recovery in underlying profitability over the next 24 months.
3. Exit P/E Multiple: 19.5x
This is a conservative multiple relative to where Stryker has historically traded. It accounts for the risk that near-term earnings growth remains below historical rates as the company recovers from the cyberattack and muted device demand. But it also creates potential upside if Stryker executes on margins and growth as expected.
The consensus analyst price target of around $389 per share is very close to our model’s target of $393. That close alignment provides additional validation for the assumptions embedded in our analysis.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for SYK stock through 2035 show varied outcomes based on revenue growth, margin expansion, and robotic surgery adoption rates (these are estimates, not guaranteed returns):
- Low Case: Muted medical device demand and slower robotic surgery adoption limit growth → 6.4% annual returns
- Mid Case: Steady revenue recovery and margin expansion deliver solid compounding → 9.3% annual returns
- High Case: Robotic surgery scales rapidly, and new acquisitions accelerate top-line growth → 12.0% annual returns
Going forward, Stryker’s fundamental business case remains compelling even after the cyberattack-related disruption. The model projects returns right at the 10% threshold that typically signals an attractive long-term investment opportunity.
Investors who believe medical device demand will recover strongly, and that the cyberattack was a one-time event, may find the stock’s current valuation interesting relative to its historical growth trajectory.
See what analysts think about SYK stock right now (Free with TIKR) >>>
Should You Invest in Stryker?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up SYK, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track SYK alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze the stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
